Kyverna Therapeutics, Inc. (KYTX)
8.87
-0.22
(-2.42%)
USD |
NASDAQ |
Mar 17, 14:47
Kyverna Therapeutics Enterprise Value : 231.99M for March 16, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.951B |
| CorMedix, Inc. | 516.72M |
| Castle Biosciences, Inc. | 505.47M |
| EyePoint Plc | 838.87M |
| Vistagen Therapeutics, Inc. | -35.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -36.79M |
| Total Expenses (Quarterly) | 36.79M |
| EPS Diluted (Quarterly) | -0.8473 |
| Earnings Yield | -41.95% |
| Normalized Earnings Yield | -41.95 |